Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 7—July 2010

Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008

Joseph F. WamalaComments to Author , Luswa Lukwago, Mugagga Malimbo, Patrick Nguku, Zabulon Yoti, Monica Musenero, Jackson Amone, William Mbabazi, Miriam Nanyunja, Sam Zaramba, Alex Opio, Julius J. Lutwama, Ambrose O. Talisuna, and Sam I. Okware
Author affiliations: Ministry of Heath, Kampala, Uganda (J.F. Wamala, L. Lukwago, M. Malimbo, M. Musenero, J. Amone, S. Zaramba, A. Opio, J.J. Lutwama, A.O. Talisuna, S.I. Okware); World Health Organization Country Office, Kampala (Z. Yoti, W. Mbabazi, M. Nanyunja); African Field Epidemiology Network Secretariat, Kampala (P. Nguku)

Main Article

Table 1

Case definitions for epidemiologic investigation of EHF outbreak, Bundibugyo district, Uganda, 2007–2008*

Classification Definition
Suspected case
Sudden onset of fever and at least 4 of the following symptoms in a resident of or visitor to the affected subcounties in Bundibugyo district: vomiting, diarrhea, abdominal pain, conjunctivitis, skin rash, unexplained bleeding from any body part, muscle pain, intense fatigue, difficulty swallowing, difficulty breathing, hiccups, or headache since August 1, 2007, OR sudden onset of fever in any person who had had contact with a person with suspected, probable, or confirmed EHF, OR sudden death in a person in the community without any other explanation.
Probable case
Suspected EHF in any person (dead or alive) with at least 3 of the following symptoms; vomiting, diarrhea, or unexplained bleeding from any site, conjunctivitis, or skin rash; AND with an epidemiologic link to a person with probable or confirmed EHF, OR either no specimen collected for laboratory testing or a negative laboratory result in a specimen collected 0–3 days after onset of symptoms in a person with suspected EHF.
Confirmed case
Laboratory confirmation of infection by isolation of virus from any body fluid or tissue, OR detection of viral antigen in any body fluid or tissue by antigen-detection ELISA, reverse-transcription–PCR, or immunohistochemistry, OR demonstration of serum Ebola virus–specific IgG antibodies by ELISA, with or without IgM, in any person with suspected or probable EHF.
Contact A person who had slept in the same household and/or had direct physical contact with a person (dead or alive) with suspected, probable, or confirmed EHF and/or had been exposed to an infected person or to an infected person’s secretions, excretions, tissues, or linens within 3 weeks after that person’s onset of illness.

*EHF, Ebola hemorrhagic fever; Ig, immunoglobulin.

Main Article

Page created: March 02, 2011
Page updated: March 02, 2011
Page reviewed: March 02, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.